ClinicalTrials.gov
ClinicalTrials.gov Menu

B-Receptor Signaling in Cardiomyopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01135849
Recruitment Status : Completed
First Posted : June 3, 2010
Last Update Posted : November 17, 2015
Sponsor:
Information provided by (Responsible Party):
Daniel Bernstein, Stanford University

Brief Summary:
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.

Condition or disease
Carcinomas Amyloidosis Anal Cancer Anemia Cholangiocarcinoma of the Extrahepatic Bile Duct Transitional Cell Carcinoma of Bladder Bone Marrow Transplant Failure Bone Cancer Cancer of Brain and Nervous System Breast Cancer Carcinoma of the Large Intestine Endocrine Cancer Esophageal Cancer Eye Cancer Gall Bladder Cancer Gastric (Stomach) Cancer Gastrooesophageal Cancer Gastrointestinal Stromal Tumor (GIST) Gynecologic Cancers Head and Neck Cancers Hepatobiliary Neoplasm Kidney (Renal Cell) Cancer Leukemia Lung Cancer Hodgkin Disease Lymphoma, Non-Hodgkin Mesothelioma Multiple Myeloma Myelodysplastic Syndromes (MDS) Neuroendocrine Tumors Myeloproliferative Disorders Pancreatic Cancer Prostate Cancer Skin Cancer Soft Tissue Sarcoma Testicular Cancer Thymus Cancer Thyroid Cancer

Detailed Description:

There is a strong correlation between total doxorubicin dose and anti-tumor efficacy, however, the clinical utility of doxorubicin is severely limited by its cardiotoxicity. With improved methods of detecting subtle changes in cardiac function, e.g. alterations in left ventricular wall stress (1), the incidence of doxorubicin cardiotoxicity is now appreciated to be much higher than previously suspected, documented in 65% of long-term survivors of childhood cancer, even at doses as low as 228 mg/m2. This cardiotoxicity is dose-related, and higher doses are related to a higher incidence of clinical heart failure (2). Doxorubicin's cardiotoxicity is thought to be mediated through the generation of free radicals and through mitochondrial and membrane damage.

We wish to determine whether beta-receptor genotype affects anthracycline-induced cardiomyopathy. We will correlate beta-receptor genotype with difference in wall stress post-anthracycline exposure, and with difference in shortening fraction. We plan to recruit 300 patients over a two-year period. Inclusion criteria includes past exposure to anthracycline for cancer treatment and an echocardiogram 6 - 48 months after exposure to anthracyclines.

The mean difference in 1.) wall stress and 2.) shortening fraction between each minor allele subgroup and wild type subgroup, for both beta-1 and beta-2 will be assessed using unpaired t-test analyses . We will assess through multivariate linear regression whether there are interactions between differences in wall stress or fractional shortening and other variables such as age, gender, dose of anthracycline, type of anthracycline given, and time between anthracycline exposure and echocardiogram. Those who receive other cardiotoxic drugs (such as trastuzumab for breast cancer) will be analyzed separately.


Study Type : Observational
Actual Enrollment : 99 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: B-Receptor Signaling in Cardiomyopathy
Study Start Date : November 2008
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010





Primary Outcome Measures :
  1. Development of cardiomyopathy [ Time Frame: Within 5 years after receiving anthracyclines. ]
    Decrease in fractional shortening below normal (<28%)


Biospecimen Retention:   Samples Without DNA
cheek swab or blood drawn for DNA extraction


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients exposed to anthracycline who have had an echocardiogram at least six months after initial exposure.
Criteria

Inclusion Criteria:1.) Past exposure to anthracycline chemotherapy for cancer

2.) Echocardiogram at least six months after exposure to anthracyclines (in patients over the age of 40, the echocardiogram must be obtained within 6 - 48 months of anthracycline exposure)

3.) Ability to understand and the willingness to sign a written informed consent document.

We have no age, gender, or ethnic background limitations. Due to the increased frequency of cardiovascular disease from other causes in adults over 40 years, we will limit enrollment to those patients with an echocardiogram 6 - 48 months after the completion of anthracycline exposure. Children will be included and will be eligible if they have an echocardiogram at least 6 months after completion of anthracycline treatment..

Exclusion Criteria:1.) Congenital heart disease (other than patent foramen ovale)

2.) Pre-existing cardiomyopathy before anthracycline administration

3.) Patients with Down syndrome

4.) Patients receiving B-blocker therapy at the time of anthracycline exposure

5.) Pregnant patients (if their echocardiogram was obtained either during pregnancy or within three months of pregnancy)

All participants will be cancer survivors. To minimize bias from post-partum cardiomyopathy, pregnant patients will be excluded if their echocardiogram was obtained during pregnancy or within three months of pregnancy. HIV-positive persons will not be excluded from the study.

Of note, some patients receive a MUGA (multigated acquisition) study to evaluate left ventricular ejection fraction. Patients who receive only a MUGA scan will NOT be included in the study - an echocardiogram is necessary


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01135849


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Daniel Bernstein
Investigators
Principal Investigator: Daniel Bernstein Stanford University

Responsible Party: Daniel Bernstein, Professor, Stanford University
ClinicalTrials.gov Identifier: NCT01135849     History of Changes
Other Study ID Numbers: PEDSVAR0038
SU-11172008-1345 ( Other Identifier: Stanford University )
First Posted: June 3, 2010    Key Record Dates
Last Update Posted: November 17, 2015
Last Verified: November 2015

Additional relevant MeSH terms:
Carcinoma
Multiple Myeloma
Pancreatic Neoplasms
Myelodysplastic Syndromes
Preleukemia
Head and Neck Neoplasms
Urinary Bladder Neoplasms
Esophageal Neoplasms
Cardiomyopathies
Sarcoma
Mesothelioma
Thyroid Neoplasms
Neuroendocrine Tumors
Cholangiocarcinoma
Amyloidosis
Skin Neoplasms
Gastrointestinal Stromal Tumors
Hodgkin Disease
Carcinoma, Transitional Cell
Anus Neoplasms
Myeloproliferative Disorders
Lymphoma, Non-Hodgkin
Testicular Neoplasms
Bone Neoplasms
Osteosarcoma
Eye Neoplasms
Gallbladder Neoplasms
Thymus Neoplasms
Endocrine Gland Neoplasms
Brain Neoplasms